These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28314271)

  • 1. Identification of Methylation Profiles of Cancer-related Genes in Circulating Tumor Cells Population.
    Lyberopoulou A; Galanopoulos M; Aravantinos G; Theodoropoulos GE; Marinos E; Efstathopoulos EP; Gazouli M
    Anticancer Res; 2017 Mar; 37(3):1105-1112. PubMed ID: 28314271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.
    Bagci B; Sari M; Karadayi K; Turan M; Ozdemir O; Bagci G
    Cancer Biomark; 2016 Jun; 17(2):133-43. PubMed ID: 27540971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
    Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
    Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer.
    Kondo Y; Hayashi K; Kawakami K; Miwa Y; Hayashi H; Yamamoto M
    BMC Cancer; 2017 May; 17(1):311. PubMed ID: 28468669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.
    Nagasaka T; Sasamoto H; Notohara K; Cullings HM; Takeda M; Kimura K; Kambara T; MacPhee DG; Young J; Leggett BA; Jass JR; Tanaka N; Matsubara N
    J Clin Oncol; 2004 Nov; 22(22):4584-94. PubMed ID: 15542810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.
    Buim ME; Fanelli MF; Souza VS; Romero J; Abdallah EA; Mello CA; Alves V; Ocea LM; Mingues NB; Barbosa PN; Tyng CJ; Chojniak R; Chinen LT
    Cancer Biol Ther; 2015; 16(9):1289-95. PubMed ID: 26252055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.
    Park HW; Kang HC; Kim IJ; Jang SG; Kim K; Yoon HJ; Jeong SY; Park JG
    Int J Cancer; 2007 Jan; 120(1):7-12. PubMed ID: 17013898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
    Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
    Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma.
    Yagi K; Takahashi H; Akagi K; Matsusaka K; Seto Y; Aburatani H; Nakajima A; Kaneda A
    Am J Pathol; 2012 Feb; 180(2):616-25. PubMed ID: 22115708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer.
    Danese E; Minicozzi AM; Benati M; Montagnana M; Paviati E; Salvagno GL; Lima-Oliveira G; Gusella M; Pasini F; Lippi G; Guidi GC
    PLoS One; 2015; 10(5):e0126417. PubMed ID: 25946211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization.
    Sawada T; Yamamoto E; Suzuki H; Nojima M; Maruyama R; Shioi Y; Akasaka R; Kamimae S; Harada T; Ashida M; Kai M; Adachi Y; Yamamoto H; Imai K; Toyota M; Itoh F; Sugai T
    Genes Chromosomes Cancer; 2013 Feb; 52(2):140-9. PubMed ID: 23073979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
    Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
    Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis.
    Aoyagi H; Iida S; Uetake H; Ishikawa T; Takagi Y; Kobayashi H; Higuchi T; Yasuno M; Enomoto M; Sugihara K
    Oncol Rep; 2011 Mar; 25(3):789-94. PubMed ID: 21174064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors.
    Poeta ML; Massi E; Parrella P; Pellegrini P; De Robertis M; Copetti M; Rabitti C; Perrone G; Muda AO; Molinari F; Zanellato E; Crippa S; Caputo D; Caricato M; Frattini M; Coppola R; Fazio VM
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1133-43. PubMed ID: 22927297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
    Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
    Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients.
    Li Y; Monzo M; Moreno I; Martinez-Rodenas F; Hernandez R; Castellano JJ; Canals J; Han B; Muñoz C; Navarro A
    Int J Colorectal Dis; 2020 May; 35(5):805-813. PubMed ID: 32088737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method.
    Yang MJ; Chiu HH; Wang HM; Yen LC; Tsao DA; Hsiao CP; Chen YF; Wang JY; Lin SR
    Ann Surg Oncol; 2010 Feb; 17(2):624-33. PubMed ID: 19937133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.